José DA GLORIA
José Da Gloria is the Chief Financial Officer of Diaccurate. He is also the CFO for other Medtechs and Biotechs companies of the Truffle Capital fund portfolio (Holistick Medical, Artedrone, Skinosive, Pk Med, BariaTek Medical, Caranx Medical and Skinnate) he is also a member of the audit committee of Affluent Medical and Carbios.
Before joining Caranx Medical Avant José was the CFO and Executive Director of Vexim between 2014 and 2018, a French publicly listed company (Euronext growth) that has developed and marketed an innovative medical device to treat vertebral compression fractures (SpineJack). Vexim was acquired by Stryker in 2017 for a total value of close to 200 million US dollars. He also participated in the launch of a French start-up of cloud computing: Cloudwatt now part of Orange Business Services as head of Finance. José was, from 2010 till 2013, Financial controller of a $250 million International division at ev3, a US medical device company acquired in 2010 by Covidien (now Medtronics), specialized in the vascular implants. He participated in the business development in the emerging countries (Latin America and Asia) as well as the financial, logistic and fiscal integration of the ev3 entities inside Covidien. Further to this integration, he joined Covidien as the EMEA FP&A Director, a €2.5 billion Revenue. From 2008 till 2010, he was Finance Planning and Analysis manager and then Finance controller for the international division of ev3. He began his career in 2000 in the IT industry as FP&A analyst and took various finance and leadership roles inside Dell inc.
He is a university graduate of Versailles with a Master’s degree in Economy and Finance.